BACKGROUND: A dialysate calcium concentration of 2.5 meq/l (1.25 mmol/l) is currently recommended, but there are not enough studies to examine the effects of this calcium concentration on clinical outcomes. We explored the effects of this calcium concentration on health-related quality of life (HRQOL) in hemodialysis patients. METHODS: The dialysate calcium concentration was lowered from 3.0 meq/l to 2.5 meq/l in 78 hemodialysis patients. The Medical Outcomes Study (MOS) Short Form 36 (SF-36) norm-based scores, the doses of recombinant human erythropoietin (rHuEpo), and the serum levels of corrected calcium, phosphorus, intact parathyroid hormone (i-PTH), and hemoglobin were compared at baseline and 8 months after the change of dialysate calcium concentration. RESULTS: Seventy-three patients completed the study. Mean changes in SF-36 scores were: physical functioning, -2.4; role physical, -3.9; bodily pain, -3.4; general health perception, -1.5; vitality, -2.2; social functioning, -1.9; role emotional, -2.0; mental health, -2.0. The declines of scores for role physical and bodily pain were significant. Serum i-PTH levels increased significantly, from 212 pg/ml to 278 pg/ml, while the doses of rHuEpo and serum levels of corrected calcium, phosphorus, and hemoglobin did not change significantly. CONCLUSIONS: A dialysate calcium concentration of 2.5 meq/l was not shown to have positive effects on HRQOL.
BACKGROUND: A dialysate calcium concentration of 2.5 meq/l (1.25 mmol/l) is currently recommended, but there are not enough studies to examine the effects of this calcium concentration on clinical outcomes. We explored the effects of this calcium concentration on health-related quality of life (HRQOL) in hemodialysis patients. METHODS: The dialysate calcium concentration was lowered from 3.0 meq/l to 2.5 meq/l in 78 hemodialysis patients. The Medical Outcomes Study (MOS) Short Form 36 (SF-36) norm-based scores, the doses of recombinant humanerythropoietin (rHuEpo), and the serum levels of corrected calcium, phosphorus, intact parathyroid hormone (i-PTH), and hemoglobin were compared at baseline and 8 months after the change of dialysate calcium concentration. RESULTS: Seventy-three patients completed the study. Mean changes in SF-36 scores were: physical functioning, -2.4; role physical, -3.9; bodily pain, -3.4; general health perception, -1.5; vitality, -2.2; social functioning, -1.9; role emotional, -2.0; mental health, -2.0. The declines of scores for role physical and bodily pain were significant. Serum i-PTH levels increased significantly, from 212 pg/ml to 278 pg/ml, while the doses of rHuEpo and serum levels of corrected calcium, phosphorus, and hemoglobin did not change significantly. CONCLUSIONS: A dialysate calcium concentration of 2.5 meq/l was not shown to have positive effects on HRQOL.
Authors: S Bro; J B Bjorner; P Tofte-Jensen; S Klem; B Almtoft; H Danielsen; M Meincke; M Friedberg; B Feldt-Rasmussen Journal: Perit Dial Int Date: 1999 Nov-Dec Impact factor: 1.756
Authors: T Shinzato; S Nakai; T Akiba; C Yamazaki; R Sasaki; T Kitaoka; K Kubo; T Shinoda; K Kurokawa; F Marumo; T Sato; K Maeda Journal: Nephrol Dial Transplant Date: 1997-05 Impact factor: 5.992
Authors: Donna L Mapes; Antonio Alberto Lopes; Sudtida Satayathum; Keith P McCullough; David A Goodkin; Francesco Locatelli; Shunichi Fukuhara; Eric W Young; Kiyoshi Kurokawa; Akira Saito; Jürgen Bommer; Robert A Wolfe; Philip J Held; Friedrich K Port Journal: Kidney Int Date: 2003-07 Impact factor: 10.612